Respiratory Distress Syndrome in Premature Infant — Effect of Chest Physiotherapy on the Development of Preterm Infants.
Citation(s)
Abman SH, Bancalari E, Jobe A The Evolution of Bronchopulmonary Dysplasia after 50 Years. Am J Respir Crit Care Med. 2017 Feb 15;195(4):421-424. doi: 10.1164/rccm.201611-2386ED. No abstract available.
Baker CD, Abman SH, Mourani PM Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia. Pediatr Allergy Immunol Pulmonol. 2014 Mar 1;27(1):8-16. doi: 10.1089/ped.2013.0323.
Baker CD, Abman SH Impaired pulmonary vascular development in bronchopulmonary dysplasia. Neonatology. 2015;107(4):344-51. doi: 10.1159/000381129. Epub 2015 Jun 5.
Bancalari E, Jain D Bronchopulmonary Dysplasia: 50 Years after the Original Description. Neonatology. 2019;115(4):384-391. doi: 10.1159/000497422. Epub 2019 Apr 11.
Bayley, N (2015). Escala Bayley de desarrollo infantil -III (Bayley-III). España: Person Educación
Camy LF, Mezzacappa MA Expiratory flow increase technique and acid esophageal exposure in infants born preterm with bronchopulmonary dysplasia. Pediatr Phys Ther. 2011 Winter;23(4):328-33. doi: 10.1097/PEP.0b013e31823565c3.
Cohen, J (1988). Statistical Power Analysis for the Behavioral Sciences. 2nd. edit., Hillsdale, N.J., Erlbaum (Primera edición, 1977 New York: Academic Press)
Fernández Rego, F J. y Gómez-Conesa, A. (2014). Importancia del tratamiento de Fisioterapia en el síndrome de dificultad respiratoria y en la displasia broncopulmonar. Fisioterapia, 245-246. https://doi.org/10.1016/j.ft.2014.09.004
Gasquez Góngora, JJ (2010). Displasia broncopulmonar. Revista mexicana de Pediatría, 77(1), 27-31.
Gómez Conesa, A , Fernández-Rego, F.J., y Agueras Arenas, J.J. (2016). Vojta therapy in the reduction of perinatal risk in preterm infants with respiratory distress syndrome and bronchopulmonary dysplasia. Physiotherapy, 102, 199. DOI:https://doi.org/10.1016/j.physio.2016.10.242
Gonzáalvez Armengod, C , Omaña Alonso, MF. (2006). Protocolos de Neonatología: Síndrome de diestrés respiratorio neonatal o enfermedad de membrana hialina. Bol Pediatr, 46 (1), 160-165.
Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2015 Jul 15;192(2):134-56. doi: 10.1164/rccm.201412-2142PP.
Morales, M S. L., Grenfell, A. M. G., Vargas, M. P. S., y Ramos, J. D. T. (2008). La nueva displasia broncopulmonar. Parte I. Revista del Instituto Nacional de Enfermedades Respiratorias, 21(3), 221-234.
Pallás, C , Cruz, J., y Medina, C. (2001). Apoyo al desarrollo de los niños nacidos demasiado pequeños, demasiado pronto. Madrid: Ministerio de trabajo y asuntos sociales. Documentos 56/2000. Real Patronato sobre discapacidad.
Pandya YS, Shetye J, Nanavati R, Mehta A Resolution of lung collapse in a preterm neonate following chest physiotherapy. Indian J Pediatr. 2011 Sep;78(9):1148-50. doi: 10.1007/s12098-011-0397-x. Epub 2011 Mar 9.
Piper, M C., & Darrah, J. (1994). Motor assesssment of the developing infant. Recuperado de https://www.fylkesmannen.no/contentassets/880e78d8d11e415eb33008d556107d69/motor-assesssment-of-the-developing-infant---ellen-roseth.pdf
Salcedo Posadas, A , González, E., Herráiz, R., y Rodriguez Cimadevilla, J.L. (2014). Normas para control y seguimiento de niños con displasia broncopulmonar (enfermedad pulmonar crónica en la infancia). Salud(i)Ciencia, 20, 730-737.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.